Research Shows Weight Loss Drug Semaglutide Offers Cardiovascular Benefits by Reducing Heart Disease Risks

In a recent announcement, Novo Nordisk has unveiled compelling evidence that semaglutide 2.4 mg offers significant cardiovascular benefits.

These findings underscore the pressing need for a new approach to tackling the growing crisis of obesity, which is closely linked to heightened risks of heart disease.

Can Semaglutide be the game-changer we have been waiting for in the battle against obesity and its cardiovascular risks?

The connection between obesity and increased cardiovascular risks is multifaceted, with a cascade of adverse effects that can significantly impact heart health.

Plaque Formation

One of the most prominent links between these two is the accumulation of excess body fat, which can lead to fatty material building up within the arteries.

This process, known as atherosclerosis, occurs as cholesterol and other substances in the blood form plaque deposits on the inner walls of arteries. As these deposits accumulate, they narrow the arteries and restrict blood flow.

When this occurs in the arteries that carry blood to the heart, it can set the stage for a potentially life-threatening event – a heart attack.

High Blood Pressure

Obese individuals often require more blood to supply oxygen and nutrients to their larger bodies, which increases blood volume.

The body must generate more pressure to pump this blood volume effectively, causing elevated blood pressure levels.

Hypertension is a well-established risk factor for cardiovascular diseases, making it a significant concern among the obese population.

Metabolic Syndrome

Obesity and diabetes frequently go hand in hand, forming another intricate link in the chain of cardiovascular risks known as metabolic syndrome.

In obese individuals, the likelihood of developing type 2 diabetes is significantly higher. Obesity is responsible for 80-85% of the risk of diabetes, while obese people have an 80-fold higher chance of getting the disease than those with a BMI under 22.

Elevated blood sugar levels in diabetes can lead to more plaque formation in the arteries, obstructing blood flow and hampering its ability to reach different body areas.

The good news is that even a modest amount of weight loss can yield cardiovascular benefits, reducing risk factors and preventing cardiovascular diseases.

Lowered Hypertension

Weight loss reduces the pressure on arterial walls, enabling blood to flow more freely. This benefit is meaningful as hypertension is a silent killer, often symptomless until it leads to severe complications.

Improved Insulin Sensitivity

Weight loss also improves insulin sensitivity and reduces insulin resistance. People with both obesity and diabetes can experience improved conditions through weight loss, potentially achieving remission of diabetes.

Improved Lipid & Inflammatory Profiles

Weight loss helps reduce levels of triglycerides and bad cholesterol (LDL) while increasing good cholesterol (HDL). Also, it can lower inflammation in the body, another critical contributor to cardiovascular diseases.

The most compelling finding is that the degree of weight loss is directly proportional to the cardiovascular benefits gained, as follows:

• 5% of body weight loss can reduce high blood pressure and high blood glucose
• 5-10% of body weight loss can improve lipid profiles and halt diabetes progression
• 10-15% of body weight loss can reduce the risk of cardiac events
• Over 15% of body weight loss can lead to a reduction in cardiovascular mortality

Semaglutide, commercially known as Ozempic or Wegovy, is a remarkable medication initially developed as an antidiabetic drug.

However, its unique properties have led to its FDA approval for weight loss, particularly in individuals with diabetes and weight-related conditions.

Semaglutide belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. It mimics the action of the natural GLP-1 hormone within the body.

How Does Semaglutide Work for Diabetes?

Semaglutide’s antidiabetic function revolves around regulating blood sugar levels. When an individual’s blood sugar levels rise after a meal, semaglutide stimulates the body’s production of insulin, helping lower blood sugar levels and managing diabetes.

How Does Semaglutide Work for Weight Loss?

For weight management, semaglutide operates through a multifaceted approach:

• Semaglutide suppresses appetite by delaying the time it takes for the stomach to empty, reducing the quantity of food consumed.
• Semaglutide influences the brain signaling associated with appetite, preventing overeating and cravings for energy-dense foods.

This dual action on both satiety and appetite makes semaglutide an effective tool for weight loss in people struggling with obesity or related conditions.

In August 2023, Novo Nordisk, the pharmaceutical company responsible for producing semaglutide, made an official announcement.

Accordingly, semaglutide 2.4 mg (Wegovy) demonstrated a significant reduction in the risk of major adverse cardiovascular events (MACEs) by 20% in adults with obesity.

The results came from a double-blinded trial called SELECT, which compared subcutaneous once-weekly semaglutide 2.4 mg to a placebo adjunct to standard care for preventing major adverse cardiovascular events for up to 5 years.

While these findings are groundbreaking, it is essential to note that the trial has yet to undergo external scientific review.

Novo Nordisk has not provided details regarding the amount of weight lost by participants in the trial, nor is it clear whether the semaglutide cardiovascular benefits were solely due to weight loss or if the drug has other mechanisms at play.

Nonetheless, the trial is a landmark that can change how obesity is perceived and treated. Novo Nordisk plans to seek approvals for an expanded label indication for semaglutide 2.4 mg in the United States and the European Union in 2023.

The time it takes for individuals to notice semaglutide cardiovascular benefits depends on how much weight they lose while using the drug.

Research has demonstrated that semaglutide can lead to a mean weight loss of 10% to 15% within 3 to 6 months. According to JAMA Network Open:

• Over 85% of participants achieved 5% weight loss
• Over 50% of participants achieved 10% weight loss
• Over 20% of participants achieved 15% weight loss
• Nearly 10% of participants achieved 20% weight loss

As previously mentioned, a weight loss of just over 15% of one’s body weight can result in a notable reduction in cardiovascular mortality, making these effects significant for individuals needing to lose weight to manage obesity and regain their health.

Regarding the time semaglutide cardiovascular benefits become apparent, it typically takes about 2 weeks for semaglutide to kick in. Some individuals may start to see results, such as around 5% of weight loss, within the first 8 weeks of treatment.

However, for most people, noticeable weight loss results are typically observed within 12 weeks of starting semaglutide.

The findings about Semaglutide cardiovascular benefits underscore the potential impact of the drug in managing weight and reducing heart disease risks associated with obesity. As Semaglutide continues to be studied, it may become an essential tool for patients and doctors in the battle against obesity and its adverse health consequences.

Yunique Medical provides FUNCTIONAL MEDICINE for optimized health and performance. We offer customized, scientifically advanced treatments to create a new state of human thriving. Why be ordinary when you can be optimal?

HUMAN 2.0 begins here!

Contact us to schedule your FREE consultation at one of our three locations in Florida – Ocala, Fruitland Park (The Villages), and Daytona.

UP NEXT:

Retatrutide: A Triple-agonist Peptide for Weight Loss, Obesity, and Diabetes
Ozempic for Weight Loss: Is It Safe? 8 Factors You Need to Know
Calorie Cycling | How the Metabolic Confusion Diet Works in Weight Loss